 | | Vol. 15.09 – 11 March, 2024 |
| |
|
|
| Scientists developed fate-mapping systems to distinguish the two routes, comparing their quantitative and functional outputs. They found that megakaryocytes were produced through the two routes with comparable kinetics and quantity under homeostasis.
[Immunity] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To find out actionable targets able to re-enforce leukemic cells vulnerability to T-ALL with anti-CD3 mAbs, including the clinically relevant Teplizumab, scientists identified the molecular program induced by T-ALL with anti-CD3 mAbs in PDXs-derived from T-ALL cases.
[Blood] |
|
|
|
| Researchers systematically ablated NFκB signaling effectors to identify core dependencies using a series of primary samples and syngeneic and patient-derived xenograft mouse models.
[Blood] |
|
|
|
| Investigators showed that within the hematopoietic lineage, HSCs have the largest mitochondrial NADPH pools, which are required for proper HSC cell fate and homeostasis.
[Cell Stem Cell] |
|
|
|
| The authors analyzed cancer evolution and clonal selection by jointly considering mutational and transcriptomic profiles of single cells acquired from tumor biopsies from 49 lung cancer samples and 51 samples with chronic myeloid leukemia.
[Genome Biology] |
|
|
|
| Scientists showed that max-gene-associated regulated multiple pro-proliferative pathways in hematopoietic cells and cooperated with the RUNX1::RUNX1T1 fusion oncoprotein to enhance leukemogenesis.
[Leukemia] |
|
|
|
| The authors characterized osteomacs (OMs) and identified megakaryocyte-induced mediators that augment the role of OM in the niche.
[Stem Cell Reports] |
| |
|
|
| Researchers conducted a retrospective cohort study of patients with SARS-CoV-2 infection within 90 days prior to hematopoietic cell transplant or CAR-T therapy between January 2020 and November 2022.
[Clinical Infectious Diseases] |
|
|
|
| Investigators evaluated the treatment outcomes and prognostic factors of 45 pediatric patients with FLT3-ITD AML who achieved complete remission before haploidentical hematopoietic stem cell transplantation from 2012 to 2021.
[Bone Marrow Transplantation] |
|
|
|
|
| The authors review the mechanisms of action of these various gene addition and gene editing approaches and describe the status of clinical trials designed to evaluate the potentially for these approaches to provide one-time functional cures to patients with transfusion-dependent β-thalassemia and sickle cell disease.
[Molecular Therapy] |
|
|
|
|
| The FDA has approved inotuzumab ozogamicin for the treatment of pediatric patients aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
[OncLive] |
|
|
|
|
| April 22 – 25, 2024
Baltimore, Maryland, United States |
|
|
|
|
|
| | University of Bristol – Bristol, England, United Kingdom |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | University Medical Center Groningen – Groningen, Netherlands |
|
|
|
| | Georg-Speyer-Haus – Frankfurt, Germany |
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
